French Sensorion SA has reported new efficacy endpoints data from SENS-401 in a Phase II study for the preservation of residual hearing loss.
Rentschler Biopharma SEIn the largest expansion in the company’s 150-year history, the Laupheim-headquartered CDMO Rentschler Biopharma SE has launched a new production line at its site in Milford, USA.
German iRhom2-targeted antibody specialist SciRhom GmbH has closed an oversubscribed €63m Series A financing that will be used to provide clinical proof of concept in autoimmune disorders.
Austrian Apeiron Biologics goes to Ligand Pharmaceuticals for US$100m.
Belgium-headquarted GCPR-screening specialist EuroscreenFast and Asian distributor GW Vitek have inked a strategic collaboration.
The European Commission has fully upheld the complaint by PharmaMar SA due to conflicts of interest of leading EMA experts in the (non-)authorisation of Aplidin.
Danish Novo Holdings A/S and Abingworth co-led the largest European Series A financing round this year. Together with existing and new investors, they put £90m into cancer ADC specialist Myricx Bio Ltd.
Merger within Ghent, Belgium: Anacura acquires OHMX.bio (both residing in neighborhood), adding multi-omics for drug discovery and diagnostics to its services.
EMA’s human medicines committee (CHMP) recommended ten medicines for approval at its June 2024 meeting.
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), located in Mont-Saint-Guibert, Belgium announced that it has signed a €37.5m loan facility agreement with the European Investment Bank (“EIB”). The agreement is backed by the European Commission’s InvestEU program. Nyxoah plans to use the funding for research and development, and for scaling-up its manufacturing capacity to meet demand in Europe and the U.S.